{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:28:53Z","timestamp":1753878533133,"version":"3.41.2"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cytomegalovirus (CMV) is the most clinically relevant infectious agent following heart transplantation (HTX). Data on the beneficial effects of prophylactic use of CMV immunoglobulins (CMVIG) are scarce.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this single\u2010center, retrospective study, we reported patient outcomes following cardiac transplantation using prophylactic CMV treatment, including CMVIG. Distinct clinically relevant outcomes were compared across different CMV risk groups (CMV D\u2212\/R\u2212, CMV D\u2212\/R+, CMV D+\/R+, and CMV D+\/R\u2212 or CMV high risk group).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 272 heart transplant procedures, performed between 1\/1\/2009 and 1\/11\/2020. Sixty\u2010one (22%) procedures belonged to the CMV high risk group, while 96 (35%), 50 (18%), and 65 (24%) were CMV D\u2212\/R\u2212, CMV D\u2212\/R+, and CMV D+\/R+, respectively. Baseline donor and recipient characteristics (sex, age, body mass index, cause of death, indication for HTX), ischemia times and baseline immunosuppressive regimens were similar across the different CMV risk groups, yet fewer patients were bridged with a mechanical circulatory support in the CMV D+\/R\u2212 group. CMV disease following cardiac transplantation was more common in the CMV D+\/R\u2212 risk group (<jats:italic>n<\/jats:italic>\u00a0=\u00a040 or 66.7%; <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.001), yet mortality and re\u2010transplantation rates, cardiac allograft vasculopathy (CAV) severity, rejection episodes, and development of donor\u2010specific antibodies (DSA), post\u2010transplant lymphoproliferative diseases (PTLD), and EBV infections were similar across all four CMV risk groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>High risk CMV D+\/R\u2212 patients had a similar survival compared to low and intermediate CMV risk groups using a prophylactic strategy combining CMVIG and viral DNA polymerase inhibitors. This may be related to a number of factors unrelated to prophylaxis strategy as two out of three CMV D+\/R\u2212 recipients developed CMV primary infection after prophylaxis was discontinued.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ctr.14848","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T15:32:21Z","timestamp":1668439941000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination prophylaxis in CMV high risk heart transplant recipients: A single center experience"],"prefix":"10.1111","volume":"37","author":[{"given":"Lucas N. L.","family":"Van Aelst","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Sciences Katholieke Universiteit Leuven  Leuven Belgium"},{"name":"Department of Cardiovascular Diseases University Hospitals Leuven  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Droogn\u00e9","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences Katholieke Universiteit Leuven  Leuven Belgium"},{"name":"Department of Cardiovascular Diseases University Hospitals Leuven  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabor","family":"V\u00f6r\u00f6s","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences Katholieke Universiteit Leuven  Leuven Belgium"},{"name":"Department of Cardiovascular Diseases University Hospitals Leuven  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Van Cleemput","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences Katholieke Universiteit Leuven  Leuven Belgium"},{"name":"Department of Cardiovascular Diseases University Hospitals Leuven  Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001094"},{"volume-title":"Fields' virology","year":"2001","author":"Fields BN","key":"e_1_2_8_3_1"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.655"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra064928"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2010.05.034"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2010.05.017"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.08.005"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.21037\/acs.2017.12.03"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","unstructured":"CallanP YonanN SanthanakrishnanK et\u00a0al.Does CMV Status Impact on Morbidity and Survival Following Heart Transplantation? A Large Multi\u2010Centre Retrospective UK Study.2020. p.S204.","DOI":"10.1016\/j.healun.2020.01.817"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204303261803"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12103"},{"key":"e_1_2_8_15_1","article-title":"Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients","volume":"2","author":"Hodson EM","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2007.00750.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001097"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000229039.87735.76"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100305"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13655"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.01.1564"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.14848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ctr.14848","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.14848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T07:48:36Z","timestamp":1692690516000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.14848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/ctr.14848"],"URL":"https:\/\/doi.org\/10.1111\/ctr.14848","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"type":"print","value":"0902-0063"},{"type":"electronic","value":"1399-0012"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"2022-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14848"}}